RENAL FUNCTION
Microalbuminuria and GFR are independent risk factors for CV disease:
NORDIL substudy
June 16, 2007 – Milan, Italy – A substudy of the Nordic trial with diltiazem has shown that microalbuminuria (MA+) is a risk factor for cardiovascular (CV) disease, independent of classical risk factors, independent of diabetes. Further, that estimated glomerular filtration rate (GFR) is also an independent risk factor for CV disease. Importantly, the presence of both MA+ and GFR has a synergistic effect and represents an even further increase in CV disease risk.
MORE>>
|
 |
METABOLIC SYNDROME
Higher risk for LVH in metabolic syndrome: PAMELA study
June 16, 2007 – Milan, Italy – Persons with the metabolic syndrome have a 2.5-fold higher risk of developing left ventricular hypertrophy (LVH) over 10 years, compared to persons with metabolic syndrome, according to data from the well-known PAMELA study of the general population of Milan, Italy, presented by Prof. R. Sega, Vimercate Hospital, Italy, at the 17th European Meeting of Hypertension. Prospective data on the development of LVH in the setting of metabolic syndrome is lacking.
MORE>> |
|
THERAPEUTIC ASPECTS
Atorvastatin associated with blood pressure reduction in small study
June 16, 2007 – Milan, Italy – A significant reduction in blood pressure in patients with high-normal blood pressure and mild to moderate hypercholesterolemia (240-270 mg/dL) with atorvastatin, compared to a moderate sodium diet, and this reduction may be associated with a vasodilatory response and marginally related to changes in total cholesterol levels.
MORE>> |
BLOOD PRESSURE CONTROL
Telemetric BP monitoring improved blood pressure control in less time
June 16, 2007 – Milan, Italy – Telemetric blood pressure monitoring (TBPM) optimized antihypertensive therapy and improved blood pressure control after 3 months and also allowed for optimizing high-dose irbesartan, on top of background antihypertensive therapy, as shown by reduction in pulse pressure, better dipping, and safety.
MORE>> |
|
|
|
METABOLIC SYNDROME
Fixed-dose combination of perindopril/ indapamide controls BP in metabolic syndrome
June 16, 2007 – Milan, Italy – The first study to assess the effect of a fixed-dose combination in persons with hypertension and the metabolic syndrome showed that perindopril/indapamide reduced blood pressure and provided good control rates. The OPTIMAX 2 results were presented by Prof. J.J. Mourad, Avicenne Hospital, Bobigny, France at the 17th European Meeting on Hypertension, held in Milan from June 15-19, 2007.
MORE>> |
|
THERAPEUTIC ASPECTS
CV effects of endurance training unaffected by beta-blockers
June 16, 2007 – Milan, Italy – In elderly patients with hypertension, endurance training provided similar cardiovascular benefits in the presence or absence of beta-blockers (BB). Measurement of lactate in capillary blood was used to determine the target exercise heart rate for each patient in the exercise group, in what appears to be the first time this lactase-based training approach has been used in such a study. Exercise training prescriptions are usually based on heart rate. The results of this study were presented by Prof. T. Westhoff, Berlin, Germany, at the 17th European Meeting on Hypertension, held in Milan from July 15-19, 2007.
MORE>> |
|
SLEEP APNEA AND HYPERTENSION
OSAS, inflammation and metabolic syndrome
June 16, 2007 – Milan, Italy – Obstructive sleep apnea (OSA) is a risk factor for cardiovascular (CV) events. An observational case control study of about 1400 men followed prospectively for 10 years, showed the odds ratio for a fatal CV event was 2.87 and for a nonfatal CV event was 3.17 in the presence of untreated OSA. About 15-35% had hypertension.
MORE>> |
|
